Table 4.

Outcomes of selected SLE patients with aggressive immunosuppression close to PH onset.

Variables1234567
Admission age, yrs34.157.834.343.733.227.433.2
SexFFFFFFF
SLEDAI-2K113212021207
Aggressive immunosuppression
  Pulse MP, days before PH+, 13+, 3+, 28
  RTX, days before PH+, 68+, 140
  Pulse MP, days after PH+, 11+, 9+, 0+, 6
Intensive care++++++
  ETT+MV/ECMO+/−+/−+/−+/++/−+/−−/−
  APACHE II273224262426NA
  SOFA121389611NA
Pathogens in BALF
  CMV/PJP+/−+/++/++/−
  BacteriaSM, AB
Bloodstream infectionSMSM, ABCMVBC, CA
90-day mortality+++
180-day mortality++++
  • SLE: systemic lupus erythematosus; AB: Acinetobacter baumanii; APACHE II: Acute Physiology and Chronic Health Evaluation II; BALF: bronchoalveolar lavage fluid: BC: Bacillus cereus; CA: Candida albicans; CMV: cytomegalovirus pneumonia; ECMO: extracorporeal membrane oxygenation; ETT+MV: endotracheal intubation + mechanical ventilation; NA: not applicable; MP: methylprednisolone; PH: pulmonary hemorrhage; PJP: Pneumocystic jiroveci pneumonia; RTX: rituximab; SLEDAI-2K: SLE Disease Activity Index 2000; SM: Stenotrophomonas maltophilia; SOFA: sequential organ failure assessment.